Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâ€™s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	SEK 3.250	-1.22%	173,438
03/09/26	SEK 3.290	+0.30%	110,005
02/09/26	SEK 3.280	-0.61%	312,923
01/09/26	SEK 3.300	+3.12%	268,442
31/08/26	SEK 3.200	+0.63%	178,120

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 02:00:00 05/09/26 am AEST			5-day change	1st Jan Change
3.250 ^SEK	-1.22%		+2.20%	+121.09%

26/08	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
23/07	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI

Market Cap	343M 35.84M 30.84M 29.02M 26.51M 49.59M 3.38B 49.73M 133M 1.74B 135M 132M 5.59B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	343M 35.84M 30.84M 29.02M 26.51M 49.59M 3.38B 49.73M 133M 1.74B 135M 132M 5.59B	EV / Sales 2026 *	3.95x	EV / Sales 2027 *	3.54x
Free-Float	72.16%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SPRINT	Delayed
Deutsche Boerse AG	5JA1	Delayed
Börse Stuttgart	5JA1	Delayed
Boerse Muenchen	5JA1	Real-time

26/08	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
23/07	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI
26/06	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
18/06	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
16/06	Three stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
09/06	Calendar: Tuesday, June 9	FW
08/06	Calendar Tuesday June 9	FW
13/05	Sprint Bioscience Q1 operating loss SEK 14.3 mln	RE
13/05	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Sprint Bioscience completes strategic evaluation of STK25 program	RE
16/04	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation	CI
14/04	21 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
10/04	15 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW

Sprint Bioscience AB Stock

Stocks

SPRINT

SE0006343745

Biotechnology & Medical Research

Valuation : Sprint Bioscience AB

Chart: Sprint Bioscience AB

Latest news : Sprint Bioscience AB

Analysts' recommendations : Sprint Bioscience AB

Press Releases : Sprint Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors : Sprint Bioscience AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

02/09	Sprint Bioscience (Q2 review): Continued positive progress	AQ
13/08	Sprint Bioscience's Upcoming Conferences and Investor Events	AQ
23/07	Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development	AQ
04/06	Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company	AQ
19/05	Sprint Bioscience (Q1 Review): Momentum in the business	AQ

1 day	-1.22%
1 week	+2.20%
Current month	+1.56%
1 month	-4.97%
3 months	-5.25%
6 months	+72.41%
Current year	+121.09%

1 week	3.1	3.38
1 month	2.77	3.59
Current year	1.36	4.59
1 year	0.51	4.59
3 years	0.36	4.59
5 years	0.36	5.4
10 years	0.36	41.5

Manager	Title	Age	Since
Johan Emilsson CEO	Chief Executive Officer	42	01/10/2023
Martin Andersson CTO	Chief Tech/Sci/R&D Officer	55	01/01/2009
Jenni Björnulfson DFI	Director of Finance/CFO	55	04/05/2026

Director	Title	Age	Since
Nils Rune Nordlander CHM	Chairman	70	01/01/2010
Fredrik Lehmann BRD	Director/Board Member	50	01/01/2019
Björn Magnus Sjöstrand CHM	Chairman	58	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPRINT BIOSCIENCE AB	-1.22%	+2.20%	+432.79%	+31.05%	35.84M
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+88.96%	67.98B
ARGENX SE	-2.06%	-0.18%	+39.67%	+85.24%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+377.83%	27.58B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-13.58%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+33.13%	+14.91%	25.74B
GENMAB A/S	-1.46%	+0.42%	+23.61%	-16.76%	20.09B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+375.70%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-6.60%	+559.57%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+165.57%	14.62B
Average	-1.36%	+0.45%	+81.71%	+166.85%	27.91B
Weighted average by Cap.	-1.52%	+0.18%	+38.42%	+139.41%

	2026 *	2027 *
Net sales	86.8M 9.07M 7.81M 7.35M 6.71M 12.55M 857M 12.59M 33.68M 440M 34.07M 33.33M 1.42B	96.8M 10.12M 8.71M 8.19M 7.48M 14M 955M 14.04M 37.56M 490M 37.99M 37.17M 1.58B
Net income	-	-
Net Debt	-	-